Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High or Mismatch Repair Deficient , Who Have Di

source https://finance.yahoo.com/news/fda-approves-keytruda-pembrolizumab-plus-215600746.html?.tsrc=rss